Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma

摘要

Anaplastic lymphoma kinase negative anaplastic large cell lymphoma (ALK- ALCL) is a definiteentity in the WHO 2016 Classification that represents 2–3% of non-Hodgkin lymphoma (NHL)and 12% of T-cell NHL cases. ALK- ALCL lacks ALK protein expression, but expresses CD30and has morphologic features similar to ALK positive anaplastic large cell lymphoma (ALK+ALCL). Some studies indicate that ALK- ALCL and ALK+ ALCL possess different molecular andgenetic characteristics. Besides, ALK- ALCL is worse than ALK+ ALCL in terms of treatmentoutcome, prognosis, and long-term survival. This review is aimed at summarizing informationabout ALK- ALCL, especially with respect to the treatment and prognosis.